Strides Pharma Science (NSE:STAR) Cyclically Adjusted Revenue per Share: ₹460.71 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:STAR Strides Pharma Science Ltd NSE:STAR
71 GF Score
Price ₹993.60
GF Value ₹853.06
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Strides Pharma Science Cyclically Adjusted Revenue per Share?

Strides Pharma Science NSE:STAR +0.75% 71 Cyclically Adjusted Revenue per Share is ₹460.71 as of Jun. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 71/100 and a GF Value™ of ₹853.06 (Modestly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Strides Pharma Science's adjusted revenue per share for the three months ended in Jun. 2026 was ₹137.255. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹460.71 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Strides Pharma Science's average Cyclically Adjusted Revenue Growth Rate was 3.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Strides Pharma Science was 5.60% per year. The lowest was 4.30% per year. And the median was 4.95% per year.

As of today (2026-08-25), Strides Pharma Science's current stock price is ₹993.60. Strides Pharma Science's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹460.71. Strides Pharma Science's Cyclically Adjusted PS Ratio of today is 2.16.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Strides Pharma Science was 2.56. The lowest was 0.32. And the median was 0.99.


Strides Pharma Science  (NSE:STAR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Strides Pharma Science's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=993.60/460.71
=2.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Strides Pharma Science was 2.56. The lowest was 0.32. And the median was 0.99.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Strides Pharma Science Cyclically Adjusted Revenue per Share Related Terms


Strides Pharma Science Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Cyclically Adjusted Revenue per Share Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 376.60 399.30 416.72 443.67 452.42

Strides Pharma Science Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 446.35 448.58 451.90 452.42 460.71

NSE:STAR vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strides Pharma Science Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Strides Pharma Science's Cyclically Adjusted PS Ratio falls into.


NSE:STAR
71GF Score
Strides Pharma Science Ltd NSE:STAR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Strides Pharma Science's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=137.255/167.3573*167.3573
=137.255

Current CPI (Jun. 2026) = 167.3573.

Strides Pharma Science Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 91.445 105.961 144.430
201612 81.610 105.196 129.834
201703 64.376 105.196 102.416
201706 70.477 107.109 110.120
201709 85.904 109.021 131.870
201712 81.075 109.404 124.022
201803 73.047 109.786 111.352
201806 52.643 111.317 79.145
201809 57.975 115.142 84.266
201812 63.627 115.142 92.481
201903 60.940 118.202 86.282
201906 75.891 120.880 105.071
201909 79.869 123.175 108.518
201912 81.750 126.235 108.381
202003 58.470 124.705 78.468
202006 87.266 127.000 114.997
202009 88.527 130.118 113.863
202012 92.772 130.889 118.620
202103 94.014 131.771 119.404
202106 76.754 134.084 95.801
202109 80.421 135.847 99.075
202112 88.468 138.161 107.163
202203 90.938 138.822 109.631
202206 104.667 142.347 123.057
202209 99.831 144.661 115.494
202212 95.750 145.763 109.935
202303 100.314 146.865 114.311
202306 103.289 150.280 115.026
202309 110.639 151.492 122.226
202312 109.755 152.924 120.114
202403 95.575 153.035 104.520
202406 114.498 155.789 123.000
202409 126.695 157.882 134.298
202412 125.276 158.323 132.425
202503 129.186 157.552 137.226
202506 121.520 159.755 127.303
202509 132.484 162.289 136.621
202512 129.568 163.281 132.803
202603 143.561 164.272 146.257
202606 137.255 167.357 137.255

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹460.71 mean?
Strides Pharma Science (NSE:STAR) has a Cyclically Adjusted Revenue per Share of ₹460.71 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Strides Pharma Science and its competitors.
Is Strides Pharma Science's Cyclically Adjusted Revenue per Share too high?
Strides Pharma Science's current Cyclically Adjusted Revenue per Share is ₹460.71. Overall, Strides Pharma Science has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Cyclically Adjusted Revenue per Share compare to ZTS?
Strides Pharma Science's Cyclically Adjusted Revenue per Share of ₹460.71 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current Cyclically Adjusted Revenue per Share is ₹460.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹853.06, compared to a current price of ₹993.60 — trading 16.5% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹460.71. Strides Pharma Science's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Cyclically Adjusted Revenue per Share is ₹460.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹993.60 is trading 16.5% above its estimated GF Value™ of ₹853.06. GuruFocus considers Strides Pharma Science to be Modestly Overvalued.

Key valuation signals for NSE:STAR:

  • Cyclically Adjusted Revenue per Share: ₹460.71
  • GF Value™: ₹853.06 vs. price of ₹993.60 (16.5% above fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
71GF Score

Get the complete analysis for NSE:STAR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹993.60
Price
₹853.06
GF Value